Wells Fargo lowered the firm’s price target on Morphic to $64 from $67 and keeps an Overweight rating on the shares. The firm expects 2024 to be a quieter year in terms of news and data flow, but still believes MORF-057 is de-risked in ulcerative colitis, the analyst tells investors in a research note. Wells sees shares trading up later this year into the 1H25 Phase 2b read out.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MORF: